Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey

Basit Öğe Kaydı
dc.authoridgulturk, emine/0000-0003-2836-6162
dc.authoridSERIN, Istemi/0000-0003-1855-774X
dc.authoridHacıbekiroğlu, Tuba/0000-0003-1814-5972
dc.authoridDal, Mehmet Sinan/0000-0002-5994-2735
dc.authoridBakirtas, Mehmet/0000-0003-3216-482X
dc.authorwosidKorkmaz, Serdal/IST-3736-2023
dc.authorwosidgulturk, emine/ABB-5387-2020
dc.authorwosidSERIN, Istemi/GRX-7028-2022
dc.authorwosidAlbayrak, Murat/JUU-5382-2023
dc.authorwosidHacıbekiroğlu, Tuba/ABH-2380-2020
dc.authorwosidDal, Mehmet Sinan/GXF-0283-2022
dc.contributor.authorBakirtas, Mehmet
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorYigenoglu, Tugce Nur
dc.contributor.authorGiden, Asli Odabasi
dc.contributor.authorSerin, Istemi
dc.contributor.authorBasci, Semih
dc.contributor.authorKalpakci, Yasin
dc.date.accessioned2024-05-19T14:46:20Z
dc.date.available2024-05-19T14:46:20Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractA multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least >= two lines of therapy. Patients' treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 +/- 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients.en_US
dc.identifier.doi10.1080/1120009X.2023.2208439
dc.identifier.endpage569en_US
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.issue6en_US
dc.identifier.pmid37211906en_US
dc.identifier.scopus2-s2.0-85160071567en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage563en_US
dc.identifier.urihttps://doi.org10.1080/1120009X.2023.2208439
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5499
dc.identifier.volume35en_US
dc.identifier.wosWOS:000994706500001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectProteasome Inhibitorsen_US
dc.subjectIxazomiben_US
dc.subjectLenalidomideen_US
dc.subjectMultiple Myelomaen_US
dc.subjectTurkeyen_US
dc.subjectMulticenteren_US
dc.titleReal-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu